2型糖尿病患者胰岛素联合二甲双胍治疗加用达格列净的疗效评价

Evaluation of the Efficacy of Insulin Combined with Metformin in the Treatment of Type 2 Diabetic Patients with Dapagliflozin

目的阐述2型糖尿病患者通过甘精胰岛素联合二甲双胍基础上加用达格列净治疗的效果,并探讨临床应用价值。方法2019年8月—2020年2月,研究对象抽选于该院接受治疗的2型糖尿病患者98例,对其进行随机分组,对照组患者通过甘精胰岛素注射联合二甲双胍治疗,观察组在其基础上联合达格列净治疗,监测记录各组患者治疗前后血糖及体重变化情况,比对患者每日胰岛素用量及血糖值达标时间,计算各组患者出现不良反应概率。结果观察组患者血糖水平均相较对照组更低,且体重轻于对照组(P<0.05),同时,观察组患者日胰岛素用量(0.42±0.06)U/kg明显少于对照组,空腹血糖达标时间(4.57±1.02)d较对照组用时更短(P<0.05)。此外,低血糖及其他不良反应发生率两组差异无统计学意义(P>0.05)。结论基于甘精胰岛素及二甲双胍基础上联合达格列净治疗2型糖尿病效果显著,适宜临床运用且全面推广。

Objective To describe the effect of adding dapagliflozin to insulin glargine combined with metformin in patients with type 2 diabetes,and to explore the value of clinical application.Methods From August 2019 to February 2020.The study subjects selected 98 patients with type 2 diabetes who were treated in the hospital and were randomly divided into groups.The control group received insulin glargine injection combined with metformin treatment,the observation group was combined with dapagliflozin treatment on the basis of it.The blood glucose and weight changes of the patients in each group were monitored and recorded before and after treatment.The daily insulin dosage and blood glucose reached the standard time of the patients were compared,and adverse reactions in each group were calculated.Results The blood glucose level of the observation group was lower than that of the control group,and the weight was lighter than that of the control group(P<0.05).At the same time,the daily insulin consumption(0.42±0.06)U/kg of the observation group was significantly lower than that of the control group.The standard time(4.57±1.02)d was shorter than that of the control group(P<0.05).In addition,there was no statistically significant difference in the incidence of hypoglycemia and other adverse reactions between the two groups(P>0.05).Conclusion Based on insulin glargine and metformin,the combined treatment of type 2 diabetes with dapagliflozin has a significant effect,which is suitable for clinical application and comprehensive promotion.